# Bridging the Gap to ROI: The Power of Technology Backed by Expertise

- Whitepapers  
  July 21, 2025

**Writers:** John Fitzpatrick, Chief Technology Officer and John Cogan, Chief Operating Officer

#### Summary

In the complex and highly regulated world of pharmacovigilance (PV), the accurate and timely processing of adverse events (AEs), monitoring risks and timely reporting to Authorities is critical to patient safety, regulatory compliance, and brand reputation. Qinecsa offers a comprehensive suite of solutions combining both technology and services that enables pharmaceutical, bio-pharmaceutical and medical device companies to transform and cost-optimise their vigilance operations. This whitepaper explores how Qinecsa’s integrated approach generates measurable return on investment (ROI) through efficiency gains, cost savings, improved data quality, and faster time-to-insight.

Download the whitepaper now to discover how Qinecsa can help your organization streamline pharmacovigilance operations while maximizing compliance and ROI.

## Recent Whitepapers

### [PV Insights Network White Paper: Key challenges to address pharmacovigilance needs](/content/whitepapers/pv-insights-report-key-challenges-to-address-pharmacovigilance-needs/index.html)

- February 19, 2024

[PreviousFrom Weight-loss Jabs to Ongoing Covid Vaccine Vigilance](/content/resources/ai-approach-to-pharmacovigilance-case-processing/index.html)

[NextQinecsa CEO featured in the Molecule to Market podcast](/content/resources/molecule-to-market-podcast-feature/index.html)